UROMOL

Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors

 Coordinatore AARHUS UNIVERSITETSHOSPITAL 

 Organization address address: NORREBROGADE 44
city: AARHUS
postcode: 8000

contact info
Titolo: Ms.
Nome: Christina
Cognome: Bak Pedersen
Email: send email
Telefono: +45 78455307
Fax: +45 7846 4455

 Nazionalità Coordinatore Denmark [DK]
 Sito del progetto http://www.uromol.eu/
 Totale costo 3˙922˙796 €
 EC contributo 2˙995˙347 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-02-01   -   2013-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    AARHUS UNIVERSITETSHOSPITAL

 Organization address address: NORREBROGADE 44
city: AARHUS
postcode: 8000

contact info
Titolo: Ms.
Nome: Christina
Cognome: Bak Pedersen
Email: send email
Telefono: +45 78455307
Fax: +45 7846 4455

DK (AARHUS) coordinator 0.00
2    "AARHUS UNIVERSITETSHOSPITAL, SKEJBY"

 Organization address address: Brendstrupgaardsvej 100
city: AARHUS N
postcode: 8200

contact info
Titolo: Ms.
Nome: Birgit
Cognome: Christensen
Email: send email
Telefono: +45 8949 5119
Fax: +45 8949 6018

DK (AARHUS N) participant 0.00
3    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Nome: Mark J.
Cognome: V. Rotterdam
Email: send email
Telefono: 31104391929
Fax: 31104081020

NL (ROTTERDAM) participant 0.00
4    FUNDACIO PUIGVERT

 Organization address address: CALLE CARTAGENA 340-350
city: BARCELONA
postcode: 8025

contact info
Titolo: Dr.
Nome: Ferran
Cognome: Algaba
Email: send email
Telefono: +34 934169700
Fax: +34 934169730

ES (BARCELONA) participant 0.00
5    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

 Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Mr.
Nome: Juan José
Cognome: Collazo Nieto
Email: send email
Telefono: +34 917 328 000
Fax: +34 912 246 980

ES (MADRID) participant 0.00
6    FUNDACION UNIVERSITARIA BALMES

 Organization address address: SAGRADA FAMILIA 7
city: VIC (BARCELONA)
postcode: 8500

contact info
Titolo: Dr.
Nome: Gora
Cognome: Merseburger
Email: send email
Telefono: 34938861222
Fax: 34938891063

ES (VIC (BARCELONA)) participant 0.00
7    UNIVERSIDAD POMPEU FABRA

 Organization address address: PLACA DE LA MERCE 10-12
city: BARCELONA
postcode: 8002

contact info
Titolo: Ms.
Nome: Eva
Cognome: Martin
Email: send email
Telefono: +34 935422140
Fax: +34 935422002

ES (BARCELONA) participant 0.00
8    UPPSALA UNIVERSITET

 Organization address address: SANKT OLOFSGATAN 10 B
city: UPPSALA
postcode: 751 05

contact info
Titolo: Ms.
Nome: Siw
Cognome: Utterberg
Email: send email
Telefono: 461861000000
Fax: 4618559357

SE (UPPSALA) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

construction    bladder    patient    biomarkers    markers    scores    risk    tumor    tissue    pre    nomogram    urine    patients    validation    clinic    recommendations    validated    prospective    cancer    made   

 Obiettivo del progetto (Objective)

'Bladder cancer is a recurrent and very prevalent cancer and it generates the highest cost per patient in Europe. New genomic methods have allowed identifying new markers with potential clinical application. However, due to the use of single-marker assays and poor study design, none of these markers has made it to the clinic. FGFR3 and PIK3CA mutations, expression profiles, and microsatellite alterations in tumor tissue and urine, as well as polymorphisms in immune response genes, are very promising biomarkers that predict a tumor being present in the bladder and its likelihood of progression to invade the muscle. Here, we propose to combine the best markers of bladder cancer outcome in a prospective multicenter validation study in Spain, the Netherlands, Sweden and Denmark as genetic predictors. Pre-validation of markers has been or will be made utilizing the world’s largest bladder cancer biobank (60,000 samples from 2500 patients). To achieve enough power to rapidly generate conclusive results, 2000 patients will consecutively be enrolled, and subjected to analysis, as well as follow-up for 2-4 years. The approach is a pre-defined, standard operating procedure based, prospective study with fixed end-points and testing relatively few independent variables on tumor tissue, urine and blood. To obtain a seamless introduction into the clinic we will use a mathematical approach in which the best markers are weighted based on disease models and nomogram construction, leading to a risk score applied to each patient at each visit. The team has a very strong track record in bladder cancer research, micro-array application, nomogram construction, and bio-banking. The validated biomarkers will lead to specific recommendations for changes in patient management based on the risk scores. We estimate saving of more than 40 mill Euros annually based on a reduced frequency of cystoscopies, as well as an increased survival and a better quality of life for the patients.'

Introduzione (Teaser)

Cancer clinicians need better tools when selecting treatments for patients. Validated biomarkers will lead to recommendations for improved patient management based on the risk scores.

Altri progetti dello stesso programma (FP7-HEALTH)

UNCOVER (2011)

Evaluation and development of measures to uncover and overcome bias due to non-publication of clinical trials

Read More  

BIO-NMD (2009)

Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders

Read More  

OPTIMEX (2013)

Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure

Read More